Bravo J, Baltasar Tello P, Gonzalez Garcia E, Rios Herranz E, et al. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Leuk Lymphoma 2023 May 31:1-14. doi: 10.1080/10428194.2023.2216327.
PMID: 37255002